Results 201 to 210 of about 79,311 (270)

Defying the Odds in Recurrent Glioblastoma: Complete Response following Salvage Therapy with Bevacizumab and Irinotecan - A Case Report. [PDF]

Case Rep Oncol
Yousefi A, Saraee E, Ghalehtaki R.
europepmc   +1 more source

Radiological Loco‐Regional Treatments for Cholangiocarcinoma: A Systematic Review of the Literature

Liver International, Volume 46, Issue 4, April 2026.
ABSTRACT Cholangiocarcinoma (CCA) is the second most common primary liver cancer and is being diagnosed with increasing frequency worldwide. We performed a systematic review on radiofrequency (RFA), microwave (MWA), irreversible electroporation (IRE), trans‐arterial chemoembolization (TACE) and selective internal radiation therapy (SIRT) in CCA. Thirty‐
Dimitrios Pallas, Claudia Campani, Olivier Sutter, Pierre Nahon, Nathalie Ganne‐Carrié, Olivier Seror, Jean‐Charles Nault   +6 more
wiley   +1 more source

Clinical outcomes of treatments for patients with refractory metastatic colorectal cancer: a systematic literature review and network meta-analysis. [PDF]

Ther Adv Med Oncol
Taieb J, Yahiaoui S, Choucair E, Yao W, Hauch O, Akers KG, Frederickson AM, Zaanan A.   +7 more
europepmc   +1 more source

Case Report: long complete metabolic response assessed by LAFOV FDG-PET/CT to FOLFIRINOX in first-line treatment of metastatic low-differentiated pancreatic carcinoma. [PDF]

Front Med (Lausanne)
Abgral R, Dzuko Kamga J, Metges JP, Salaun PY.   +3 more
europepmc   +1 more source

Impact of Germline <i>BRCA</i> Mutation Status on Antitumor Activity of Modified FOLFIRINOX in Patients With Advanced Pancreatic Cancer: An Exploratory Analysis. [PDF]

JCO Precis Oncol
Lee L, Tachibana Y, Matsuo S, Niina Y, Fujiyama T, Hisano T, Sugimoto R, Akashi T, Ogoshi K, Furukawa M.   +9 more
europepmc   +1 more source

Impacts of polymorphisms in drug-metabolizing enzyme and transporter genes on irinotecan toxicity and efficacy in Thai colorectal cancer patients. [PDF]

PLoS One
Akarapredee N, Atasilp C, Sukasem C, Jinda P, Sukprasong R, Jensuriyarkun J, Wongjitjanyong S, Satapornpong P, Vanwong N.   +8 more
europepmc   +1 more source

Upfront Modified FOLFOXIRI Plus Panitumumab for <i>RAS/BRAF</i> Wild-Type Metastatic Colorectal Cancer: Final Results of the Phase III TRIPLETE Study. [PDF]

J Clin Oncol
Conca V, Rossini D, Antoniotti C, Lonardi S, Pietrantonio F, Moretto R, Antonuzzo L, Randon G, Lavacchi D, Pozzo C, Marmorino F, Bergamo F, Tamburini E, Passardi A, Fazio R, Murgioni S, Borelli B, Buonadonna A, Germani MM, Formica V, Carullo M, Bordonaro R, Aprile G, Zaniboni A, Masi G, Boni L, Cremolini C.   +26 more
europepmc   +1 more source

NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial. [PDF]

ESMO Open
Macarulla T, Cid RP, Womack MS, Gracian AC, Zervoudakis A, Hatoum H, Chung V, Patel A, Paulson AS, Pant S, O'Reilly EM, Hubner RA, Van Cutsem E, Bekaii-Saab T, Zhang L, Li J, Chen H, Maxwell F, Wainberg ZA, Melisi D.   +19 more
europepmc   +1 more source

Suppression of Glucosylceramide Synthase Reverses Drug Resistance in Cancer Cells Harboring Homozygous p53 Mutants. [PDF]

Int J Mol Sci
Mostaq MS, Amin MN, Raphael A, Asbury C, Gupta A, Gu X, Han X, Sekulic D, Michalak P, Kang L, Liu YY.   +10 more
europepmc   +1 more source